Gilead Says Patent, Antitrust Claims Over HIV Drug Fail
Gilead Sciences has asked a California federal judge to dismiss a patent and antitrust lawsuit over its new HIV treatment Genvoya, saying the AIDS Healthcare Foundation failed to identify any harm...To view the full article, register now.
Already a subscriber? Click here to view full article